The BC-APPS1 study The BC-APPS1 was a single-arm, single-centre phase II study registered under the name ‘a pilot prevention study of the effects of the anti-progestin ulipristal acetate (UA) on surrogate markers of breast cancer risk’ (EudraCT registration number: 2015-001587-19; registration date: 15 July 2015; Greater Manchester-South, Research Ethics Committee number 15/NW/0478). Eligible women were premenopausal, 25–45 years of age …
Read More »Anti-progestin therapy targets hallmarks of breast cancer risk
